Summary: Bloomberg publishes an investigative article exploring how psychedelic-assisted therapy potentially could be covered by health insurance for mental health issues, highlighting MAPS’ work to support healing mental health issues through the use of MDMA-assisted therapy. “MAPS’s research on MDMA to treat post-traumatic stress disorder is seen as something of a leading indicator. Its clinical trials of MDMA for PTSD are already in advanced stages, positioning MDMA to potentially be the first psychedelic drug to be commercialized if the US Food and Drug Administration gives a green light,” writes author Tiffany Kary.
